-
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Saturday, June 23, 2018 - 10:21am | 524Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) — a clinical-stage biopharmaceutical company focused on bringing to market advanced products based on the potential of gene therapy — have been highly volatile, but the company has a "clear path" toward commercialization,...
-
Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued
Wednesday, March 14, 2018 - 9:53am | 436Read More...Bluebird bio Inc (NASDAQ: BLUE), a clinical-stage biotechnology company that focuses on therapies for the treatment of severe diseases and cancer, released "highly encouraging" clinical data in late 2017, according to Janney. But that doesn't mean investors should be aggressive buyers...
-
Bluebird's Gene Therapy Is Firing On All Cylinders
Friday, October 14, 2016 - 8:41am | 335Read More...Goldman Sachs’ Salveen Richter believes that bluebird bio Inc’s (NASDAQ: BLUE) second generation (Gen 2) LentiGlobin gene therapy is three times more potent than Gen 1, which is good news for rare blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (...
-
Maxim Raises Target On bluebird bio From $85 To $100, Maintains Buy Rating
Thursday, September 29, 2016 - 11:53am | 318Read More...With the only drug candidate that was close to approval for sickle cell now off the table, Maxim’s Jason McCarthy believes that bluebird bio Inc (NASDAQ: BLUE) could see a larger opportunity for its gene therapy, LentiGlobin. McCarthy maintained a Buy rating on the company, while raising...
-
Bluebuird Bio Crashes Nearly 30%: What's Next?
Monday, December 7, 2015 - 11:53am | 1162Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) plunged nearly 30 percent Monday morning. Bluebird reported mixed results from its ongoing studies at an industry conference. Matthew Harrison of Morgan Stanley acknowledged he "took a swing and missed," but other top Wall Street pros...
